Abstract:Background: Multiparametric magnetic resonance imaging (MRI) combined with prostate-specific-antigen density (PSAd) enhances the detection of significant prostate cancer (sPCa). However, it is unclear whether simple biparametric (bp) MRI, which reduces scan sequences, time, and cost, may be an equally effective noninvasive tool for detecting and ruling out sPCa and avoiding biopsies in biopsy-naïve men. Objective: To assess the diagnostic accuracy, predictive values, and best biopsy strategy combining bpMRI and PSAd in detecting and ruling out sPCa (Gleason score ≥7). Design, setting, and participants: Assessment of 808 biopsy-naïve men with clinical suspicion of localised PCa (prostate-specific antigen <20ng/ml, rectal examination <cT3), prospectively enrolled between November 2015 and June 2017. Intervention: All men underwent upfront bpMRI (T2- and diffusion-weighted imaging) followed by standard and targeted biopsies of any suspicious bpMRI findings. Outcome measurements and statistical analysis: Various bpMRI scores and PSAd thresholds were assessed using sPCa detection rates, predictive values, and proportion of biopsies avoided. Net benefits and decision curve analyses were compared. Combined biopsies from all men were used for reference. Results and limitations: Significant prostate cancers were detected in 283/808 (35%) men with median age and PSA (interquartile range) of 65 yr (60-70) and 6.9ng/ml (5.4-9.5), respectively. PSAd significantly influenced the predictive values of bpMRI in detecting and ruling out sPCa. The best strategy was restricting biopsies to men with highly suspicious bpMRI findings (score ≥4) or PSAd ≥0.15ng/ml/cc. This reduced the number of men requiring biopsies by 41% (329/808) and overdiagnosis of insignificant cancers by 45% (79/177), while missing only 5% (17/329) of men with sPCa. Study limitations included single-centre analysis and combined biopsies as the reference standard. Conclusions: Combination of bpMRI with PSAd improves diagnostic accuracy and predictive values for sPCa detection in biopsy-naïve men. Restricting biopsies to men with highly suspicious bpMRI findings (score ≥4) or PSAd ≥0.15ng/ml/cc was the best biopsy strategy in our patient cohort, effectively balancing risks and benefits. Studies are needed to validate our findings in other patient populations. Patient summary: This report shows that biopsy-naïve men with clinical suspicion of prostate cancer who have low- or equivocal-suspicion biparametric magnetic resonance imaging results and a low prostate-specific antigen density may not require immediate prostate biopsies.

MRI combined with PSA density in detecting clinically significant prostate cancer in patients with PSA serum levels of 4∼10ng/mL: Biparametric versus multiparametric MRI.

Rationale for Adopting a Combination of Monoparametric MRI with the Prostate-Specific Antigen in Detecting Clinically Significant Prostate Cancer: Comparison with Standard Biparametric and Multiparametric MRI

Biparametric versus multiparametric MRI in the diagnosis of prostate cancer

Values of multiparametric and biparametric MRI in diagnosing clinically significant prostate cancer: a multivariate analysis

Comparison of biparametric MRI to full multiparametric MRI for detection of clinically significant prostate cancer

Combination of 68Ga-Psma PET/CT and Multiparametric MRI Improves the Detection of Clinically Significant Prostate Cancer: A Lesion-by-Lesion Analysis.

Evaluation of clinically significant prostate cancer using biparametric magnetic resonance imaging: An evolving concept

Biparametric versus multiparametric MRI for the detection of clinically significant prostate cancer in a diverse, multiethnic population

Combination Of Ga-68-Psma Pet/Ct And Multiparametric Mri Improves The Detection Of Clinically Significant Prostate Cancer: A Lesion-By-Lesion Analysis

Biparametric prostate MRI and clinical indicators predict clinically significant prostate cancer in men with "gray zone" PSA levels

Investigating the Equivalent Performance of Biparametric Compared to Multiparametric MRI in Detection of Clinically Significant Prostate Cancer

Prebiopsy Biparametric Magnetic Resonance Imaging Combined with Prostate-specific Antigen Density in Detecting and Ruling out Gleason 7-10 Prostate Cancer in Biopsy-naïve Men

Real-time precision targeted prostate biopsy using transrectal ultrasound-magnetic resonance fusion

Improving diagnostic efficacy of primary prostate cancer with combined 99mTc-PSMA SPECT/CT and multiparametric-MRI and quantitative parameters

The value of multiparametric MRI examination using 1.5T and 3.0T with PI-RADS (version 2) in the qualitative diagnosis of clinically significant prostate cancer

Detection of clinically significant prostate cancer following initial omission of biopsy in multiparametric MRI era

Biparametric MRI-based radiomics classifiers for the detection of prostate cancer in patients with PSA serum levels of 4∼10 ng/mL

Evaluation of Multiparametric Magnetic Resonance Imaging in Detection and Prediction of Prostate Cancer.

Biparametric 3T Magnetic Resonance Imaging for prostatic cancer detection in a biopsy-naïve patient population: a further improvement of PI-RADS v2?

Diagnostic Performance of Multiparametric MRI Parameters for Gleason Score and Cellularity Metrics of Prostate Cancer in Different Zones: a Quantitative Comparison

Bi- or multiparametric MRI in a sequential screening program for prostate cancer with PSA followed by MRI? Results from the Göteborg prostate cancer screening 2 trial